Abstract: AIM: To observe the effects of moxifloxacin in treatment of hospital-acquired-pneumonia(HAP) compared with ceftriaxone.METHODS: 161 HAP patients were randomly divided into two groups.One group were given moxifloxacin 400 mg i.v. once daily followed by oral moxifloxacin 400 mg once daily.The other group were given ceftriaxone 2 g i.v. once daily followed by oral cefuroxime axetil 500 mg twice daily.RESULTS: 120 patients were eligible for per protocol efficacy analyses (60 each in the moxifloxacin and the comparator groups). Clinical success rates were 87% for moxifloxacin and 83% for the comparable group [95% CI(-9.77,15.96)].The results for secondary endpoints were similar between 2 groups. Both treatments were safe and well tolerated.CONCLUSION: Moxifloxacin i.v. /oral can be considered as a possible alternative therapy for patients with mild-to-moderate nosocomial pneumonia

Key words: Moxifloxacin, Ceftriaxone, Hospital-acquired pneumonia